Naniye Malli Cetinbas (Naniye Malli)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Mesenchymal Stem Cells

Diffusion Weighted

Immune Response

Metastatic Breast Cancer

Top Venues

Nature communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Pamela Shaw, Kelly Lancaster, Kalli C Catcott, Melissa Dolan, Rebecca Mosher, Caitlin Routhier, Chen-Ni Chin, Dorin Toader, Jeremy Duvall, Raghida Bukhalid, Timothy B Lowinger, Marc Damelin
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. Nature communications 15 (1) (2024)
Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Pamela Shaw, Kelly Lancaster, Kalli C Catcott, Melissa Dolan, Rebecca Mosher, Caitlin Routhier, Chen-Ni Chin, Dorin Toader, Jeremy Duvall, Raghida Bukhalid, Timothy B Lowinger, Marc Damelin
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. Nature communications 15 (1) (2024)
Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Pamela Shaw, Kelly Lancaster, Kalli C Catcott, Melissa Dolan, Rebecca Mosher, Caitlin Routhier, Chen-Ni Chin, Dorin Toader, Jeremy Duvall, Raghida Bukhalid, Timothy B Lowinger, Marc Damelin
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. Nature communications 15 (1) (2024)
Susan M Clardy, Alex Uttard, Bingfan Du, Kalli C Catcott, Kelly L Lancaster, Elizabeth Ditty, Jack Sadowsky, Jeffrey Zurita, Naniye Malli Cetinbas, Liuliang Qin, Stephen P Bradley, Kenneth Avocetien, Tyler Carter, Dokyong Kim, Mark Nazzaro, Ling Xu, Thomas H Pillow, Neelie T Zacharias, Gail D Lewis Phillips, Rebecca K Rowntree, Radha Iyengar, David H Lee, Marc Damelin, Dorin Toader, Timothy B Lowinger
Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios. Molecular cancer therapeutics (2023)